Wayne Winegarden, PhD: The Most Important Factor for Understanding Biosimilar Prices

Video

Wayne Winegarden, PhD, a senior fellow in business and economics at Pacific Research Institute, explains pricing issues for reference drugs and biosimilars.

The Center for Biosimilars® interviewed Wayne Winegarden, PhD, a senior fellow in business and economics at Pacific Research Institute (PRI) and director of PRI’s Center for Medical Economics and Innovation.

Winegarden said that net price is undoubtably more important than wholesale acquisition cost in regard to understanding the price of reference drugs vs biosimilars. He said that markets don’t work efficiently if pricing isn’t efficient, and having a confusing array of prices takes away that efficiency. He suggested that people to focus on systemic pricing and simplifying the way in which prices are assessed.

Related Videos
Fran Gregory, PharmD, MBA
Julie Reed, MS
Fran Gregory, PharmD, vice president of emerging therapies, Cardinal Health
Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health
Here are the top 5 biosimilar articles for the week of May 1, 2023.
Christine Baeder
Michael Kleinrock
Here are the top 5 biosimilar articles for the week of February 13th, 2023.
Michael Kleinrock
Ian Henshaw
Related Content
© 2023 MJH Life Sciences

All rights reserved.